Tiniakos D, Spandidos D A, Kakkanas A, Pintzas A, Pollice L, Tiniakos G
Department of Pathology, NIMTS Hospital, Athens, Greece.
Anticancer Res. 1989 May-Jun;9(3):715-21.
An immunohistochemical assay was used to assess expression of ras p21 and myc p62 oncogene products in human hepatocellular carcinoma (HCC) and non-neoplastic liver tissues. The monoclonal antibodies Y13 259 and Myc1-9E10, specific for ras p21 and myc p62 oncoproteins, were employed on paraffin-embedded sections. Most HCCs showed enhanced ras p21 and myc p62 expression, as indicated by staining intensity. Cirrhotic livers revealed increased myc p62 and occasionally increased ras p21 expression. HBsAg+ hepatocytes showed intense immunostaining for ras p21. Fibrotic, cholestatic, fetal and normal adult liver did not present enhancement of oncoprotein production. We suggest that combined over-expression of ras and myc oncoproteins may be important for the malignant phenotypic alteration in human HCC.
采用免疫组织化学分析方法评估人肝细胞癌（HCC）和非肿瘤性肝组织中ras p21和myc p62癌基因产物的表达。针对ras p21和myc p62癌蛋白的单克隆抗体Y13 259和Myc1 - 9E10应用于石蜡包埋切片。如染色强度所示，大多数HCC显示ras p21和myc p62表达增强。肝硬化肝脏显示myc p62表达增加，偶尔ras p21表达也增加。HBsAg阳性肝细胞对ras p21呈强免疫染色。纤维化、胆汁淤积、胎儿及正常成人肝脏未出现癌蛋白产生增强。我们认为ras和myc癌蛋白的联合过度表达可能对人类HCC的恶性表型改变具有重要意义。
